Page last updated: 2024-12-06

bromopyruvate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bromopyruvate (BrPA) is a potent inhibitor of glycolysis, a fundamental metabolic pathway that provides energy to cells. It functions by targeting and irreversibly inhibiting the enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a key step in glycolysis. This inhibition disrupts glucose metabolism, leading to the accumulation of upstream metabolites and ultimately cellular energy depletion. Bromopyruvate's ability to disrupt glycolysis has made it a subject of extensive research in various fields. Notably, it has emerged as a promising anticancer agent. Cancer cells, which often exhibit increased reliance on glycolysis for energy production, are particularly vulnerable to BrPA's inhibitory effects. Studies have shown that BrPA can effectively suppress the growth of various cancer cell lines, both in vitro and in vivo. Moreover, its ability to inhibit glycolysis has also led to investigations into its potential use as an anti-inflammatory agent, as inflammation is often associated with increased glycolytic activity. However, the clinical application of BrPA faces significant challenges due to its inherent toxicity and lack of selectivity. Current research focuses on developing more targeted and less toxic derivatives of BrPA, aiming to enhance its therapeutic potential while mitigating its adverse effects. '

3-bromopyruvic acid : A 2-oxo monocarboxylic acid that is pyruvic acid in which one of the methyl hydrogens is replaced by bromine. Synthetic brominated derivative and structural analog of pyruvic acid. Highly reactive alkylating agent. Anti-cancer drug [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID70684
CHEMBL ID177837
CHEBI ID131461
CHEBI ID95046
SCHEMBL ID8126
MeSH IDM0067549
PubMed CID6994776
CHEBI ID131592
MeSH IDM0067549

Synonyms (73)

Synonym
BPV ,
brn 1746786
nsc 62343
einecs 214-206-5
nsc 11731
3-bromo-2-oxopropionic acid
NCIOPEN2_000241
nsc-62343
nsc62343
.beta.-bromopyruvic acid
pyruvic acid, bromo-
1113-59-3
nsc-11731
propanoic acid, 3-bromo-2-oxo-
nsc11731
3-bromopyruvic acid
3-bromo-2-oxopropanoic acid
bromopyruvic acid
bromopyruvic acid, >=97.0% (t)
B1153
CHEMBL177837
CHEBI:131461
3-bp
3-bromo-2-oxopropanoic acid;3-bromopyruvic acid
bromopyruvicacid
EN300-67360
63jmv04grk ,
unii-63jmv04grk
FT-0623262
AKOS015892643
S5426
3-brpa
BRD-K92980438-001-01-7
3-bromo-2-oxo-propionic acid
beta-bromopyruvic acid
AM84337
SCHEMBL8126
bromo-2-oxopropanoic acid
J-650255
3-bromo-2-oxopropanoic acid #
3-bromo-2-keto-propionic acid
mfcd00002587
DTXSID7040940
CS-5517
HY-19992
J-511892
CHEBI:95046
hexokinase ii inhibitor ii;3-bp
bromopyruvic acid; 3-bromo-2-oxopropanoic acid
Q3608257
hexokinase ii inhibitor ii, 3-bp - cas 1113-59-3
3-bromopyruvic acid hydrate,98
AS-16146
HMS3866H13
hexokinase ii inhibitor ii, 3-bp
HMS3741K19
CCG-266336
nsc-782120
nsc782120
3-bromopyruvicacid
Z1079181768
bromopyruvate
3-BROMOPYRUVATE ,
CHEBI:131592
3-bromo-2-oxopropanoate
gtpl4517
PRRZDZJYSJLDBS-UHFFFAOYSA-M
3-bromo-2-oxo-propionate
Q27073726
DTXSID701278021
propanoic acid, 3-bromo-2-oxo-, ion(1-)
PD048941
68-38-2

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" This toxic effect of 3-BP was also proved using primary mouse hepatocytes."( Impaired mitochondrial functions contribute to 3-bromopyruvate toxicity in primary rat and mouse hepatocytes.
Červinková, Z; Drahota, Z; Endlicher, R; Hakeem, K; Kučera, O; Raad, M; Rychtrmoc, D; Sobotka, O, 2016
)
0.43
"In this study, we aimed to evaluate the toxic effects, changes in life span, and expression of various metabolism-related genes in Caenorhabditis elegans, using RNA interference (RNAi) and mutant strains, after 3-bromopyruvate (3-BrPA) treatment."( Toxicity and metabolism of 3-bromopyruvate in Caenorhabditis elegans.
Chen, G; Fu, XM; Gu, QL; Kou, W; Lan, YM; Lu, ZL; Ma, R; Yu, Y; Zhang, Y,
)
0.13

Compound-Compound Interactions

ExcerptReferenceRelevance
" Although knowledge of drug suppression is vital to avoid efficacy-reducing drug interactions or discover countermeasures for chemical toxins, drug-drug suppression relationships have not been systematically mapped."( Large-scale identification and analysis of suppressive drug interactions.
Akhmedov, M; Cansever, D; Cetiner, S; Cokol, M; Doak, A; Giaever, G; Guvenek, A; Iossifov, I; Li, S; Mutlu, B; Nislow, C; Rodriguez-Esteban, R; Roth, FP; Shoichet, B; Tasan, M; Weinstein, ZB; Yilancioglu, K, 2014
)
0.4
" Here we offer a brief review of our own contribution to the development of a photosensitizer for PDT - redaporfin - currently in Phase II clinical trials, and present data on its combination with two glycolysis inhibitors: 2-deoxyglucose and 3-bromopyruvate."( Redaporfin Development for Photodynamic Therapy and its Combination with Glycolysis Inhibitors.
Arnaut, LG; Mendes, MIP, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
alkylating agentHighly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
oxo carboxylic acidAny compound that has an aldehydic or ketonic group as well as a carboxylic acid group in the same molecule.
2-oxo monocarboxylic acidAny monocarboxylic acid having a 2-oxo substituent.
organobromine compoundA compound containing at least one carbon-bromine bond.
2-oxo monocarboxylic acid anionAn oxo monocarboxylic acid anion in which the oxo group is located at the 2-position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (18)

PathwayProteinsCompounds
superpathway of glycolysis, pyruvate dehydrogenase, TCA, and glyoxylate bypass3989
L-lysine biosynthesis I1663
photosynthetic 3-hydroxybutanoate biosynthesis (engineered)6373
TCA cycle V (2-oxoglutarate:ferredoxin oxidoreductase)1233
superpathway of L-phenylalanine biosynthesis1665
2-methylcitrate cycle I1219
superpathway of guanosine nucleotides de novo biosynthesis I2436
guanosine ribonucleotides de novo biosynthesis1535
superpathway of L-lysine, L-threonine and L-methionine biosynthesis I1994
superpathway of aromatic amino acid biosynthesis2184
chorismate biosynthesis I1559
chorismate biosynthesis from 3-dehydroquinate1037
superpathway of L-tyrosine biosynthesis1557
superpathway of chorismate metabolism56186
aspartate superpathway25122
superpathway of L-tryptophan biosynthesis1665
trans-4-hydroxy-L-proline degradation I425
3-dehydroquinate biosynthesis I531

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1762796Inhibition of bacterial L1 using meropenem as substrate incubated for 1 hr by spectrometry analysis2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID1411949Inhibition of Mycobacterium tuberculosis ICL1 expressed in Escherichia coli BL21(DE3) using DL-isocitrate as substrate incubated for 25 mins in presence of MgCl2 by 1H NMR method2017MedChemComm, Nov-01, Volume: 8, Issue:11
Development of NMR and thermal shift assays for the evaluation of
AID56936Inhibitory activity against dihydrodipicolinic acid synthase was determined1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
New analgesic drugs derived from phencyclidine.
AID1411952Binding affinity to Mycobacterium tuberculosis ICL1 expressed in Escherichia coli BL21(DE3) assessed as melting temperature at 1 mM in presence of MgCl2 by SYPRO orange dye based fluorescence assay (Rvb = 43 degC)2017MedChemComm, Nov-01, Volume: 8, Issue:11
Development of NMR and thermal shift assays for the evaluation of
AID1847353Binding affinity to NDM-1 (unknown origin) assessed as kinetic constant using cefazolin as substrate preincubated for 60 sec followed by cefazolin addition after 60 sec by isothermal titration calorimetric assay2021European journal of medicinal chemistry, Nov-05, Volume: 223Recent research and development of NDM-1 inhibitors.
AID1762794Inhibition of bacterial IMP-1 using meropenem as substrate incubated for 1 hr by spectrometry analysis2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID1762795Inhibition of bacterial ImiS expressed in Escherichia coli BL21 (DE3) using meropenem as substrate incubated for 1 hr by spectrometry analysis2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID1762792Inhibition of bacterial NDM-1 expressed in Escherichia coli BL21 (DE3) using meropenem as substrate incubated for 1 hr by spectrometry analysis2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID1762793Inhibition of bacterial VIM-2 expressed in Escherichia coli BL21 (DE3) using meropenem as substrate incubated for 1 hr by spectrometry analysis2021Bioorganic & medicinal chemistry, 05-15, Volume: 38Dipyridyl-substituted thiosemicarbazone as a potent broad-spectrum inhibitor of metallo-β-lactamases.
AID1847351Inhibition of NDM-1 (unknown origin) using cefazolin as substrate incubated for 12 hrs by Agilent UV8453 UV-Vis spectrometric analysis2021European journal of medicinal chemistry, Nov-05, Volume: 223Recent research and development of NDM-1 inhibitors.
AID1411950Inhibition of Mycobacterium tuberculosis ICL1 expressed in Escherichia coli BL21(DE3) at 100 uM using DL-isocitrate as substrate incubated for 25 mins in presence of MgCl2 by 1H NMR method2017MedChemComm, Nov-01, Volume: 8, Issue:11
Development of NMR and thermal shift assays for the evaluation of
AID1847352Inhibition of NDM-1 (unknown origin) at 16 uM using cefazolin as substrate incubated for 12 hrs by Agilent UV8453 UV-Vis spectrometric analysis relative to control2021European journal of medicinal chemistry, Nov-05, Volume: 223Recent research and development of NDM-1 inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (327)

TimeframeStudies, This Drug (%)All Drugs %
pre-199034 (10.40)18.7374
1990's34 (10.40)18.2507
2000's42 (12.84)29.6817
2010's168 (51.38)24.3611
2020's49 (14.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.79

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.79 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index58.96 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (43.79)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Reviews13 (4.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies3 (0.92%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
Other309 (95.08%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]